AstraZeneca (LSE: AZN) reported earnings on April 25. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), AstraZeneca missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue contracted. Non-GAAP earnings per share shrank significantly. GAAP earnings per share dropped significantly.

Margins dropped across the board.

Revenue details
AstraZeneca logged revenue of $6.39 billion. The 15 analysts polled by S&P Capital IQ hoped for revenue of $6.54 billion on the same basis. GAAP reported sales were 13% lower than the prior-year quarter's $7.35 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.41. The nine earnings estimates compiled by S&P Capital IQ predicted $1.36 per share. Non-GAAP EPS of $1.41 for Q1 were 22% lower than the prior-year quarter's $1.81 per share. GAAP EPS of $0.81 for Q1 were 37% lower than the prior-year quarter's $1.28 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 80.2%, 180 basis points worse than the prior-year quarter. Operating margin was 21.9%, much worse than the prior-year quarter. Net margin was 15.8%, 650 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $6.26 billion. On the bottom line, the average EPS estimate is $1.26.

Next year's average estimate for revenue is $26.33 billion. The average EPS estimate is $5.28.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 46 members out of 51 rating the stock outperform, and five members rating it underperform. Among two CAPS All-Star picks (recommendations by the highest-ranked CAPS members), two give AstraZeneca a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $47.30.

Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.